Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer

被引：6

作者：

Conley, Aliyah B. ^{[1
,2
]}

Fournier, Keith F. ^{[1
,2
]}

Sood, Anil K. ^{[1
,2
]}

Frumovitz, Michael ^{[1
,2
,3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA

来源：

OBSTETRICS AND GYNECOLOGY | 2023年 / 141卷 / 05期

关键词：

PERITONEAL CARCINOMATOSIS; WOMEN; HIPEC;

D O I：

10.1097/AOG.0000000000005154

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

BACKGROUND:Advanced or recurrent primary mucinous ovarian cancer is typically incurable and associated with short progression-free and overall survival when treated with standard chemotherapy. Novel approaches are desperately needed for women with this disease.CASES:Two patients with advanced or recurrent primary mucinous ovarian cancer were treated with secondary cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). No additional chemotherapy was administered postoperatively. Both patients achieved a complete and durable response, with no evidence of recurrence at 21 and 27 months, respectively, after CRS with HIPEC.CONCLUSION:Secondary CRS with HIPEC represents a potential therapeutic option for women with recurrent primary mucinous ovarian cancer.

引用

页码：1019 / 1023

页数：5

共 26 条

[1] NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019 [J].

Armstrong, Deborah K. ;

Alvarez, Ronald D. ;

Bakkum-Gamez, Jamie N. ;

Barroilhet, Lisa ;

Behbakht, Kian ;

Berchuck, Andrew ;

Berek, Jonathan S. ;

Chen, Lee-may ;

Cristea, Mihaela ;

DeRosa, Marie ;

ElNaggar, Adam C. ;

Gershenson, David M. ;

Gray, Heidi J. ;

Hakam, Ardeshir ;

Jain, Angela ;

Leath, Charles A., III ;

Liu, Joyce ;

Mahdi, Haider ;

Matei, Daniela ;

McHale, Michael ;

McLean, Karen ;

O'Malley, David M. ;

Penson, Richard T. ;

Percac-Lima, Sanja ;

Ratner, Elena ;

Remmenga, Steven W. ;

Sabbatini, Paul ;

Werner, Theresa L. ;

Zsiros, Emese ;

Burns, Jennifer L. ;

Engh, Anita M. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (08) :896-+

[2] Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy [J].

Chua, Terence C. ;

Moran, Brendan J. ;

Sugarbaker, Paul H. ;

Levine, Edward A. ;

Glehen, Olivier ;

Gilly, Francois N. ;

Baratti, Dario ;

Deraco, Marcello ;

Elias, Dominique ;

Sardi, Armando ;

Liauw, Winston ;

Yan, Tristan D. ;

Barrios, Pedro ;

Gomez Portilla, Alberto ;

de Hingh, Ignace H. J. T. ;

Ceelen, Wim P. ;

Pelz, Joerg O. ;

Piso, Pompiliu ;

Gonzalez-Moreno, Santiago ;

Van der Speeten, Kurt ;

Morris, David L. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) :2449-2456

[3] The Landmark Series: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for Treatment of Gastric Cancer Metastatic to Peritoneum [J].

Dineen, Sean P. ;

Pimiento, Jose M. .

ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (08) :4130-4137

[4] Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials [J].

Filis, P. ;

Mauri, D. ;

Markozannes, G. ;

Tolia, M. ;

Filis, N. ;

Tsilidis, K. .

ESMO OPEN, 2022, 7 (05)

[5] Unmasking the complexities of mucinous ovarian carcinoma [J].

Frumovitz, Michael ;

Schmeler, Kathleen M. ;

Malpica, Anais ;

Sood, Anil K. ;

Gershenson, David M. .

GYNECOLOGIC ONCOLOGY, 2010, 117 (03) :491-496

[6] Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy [J].

Glehen, O ;

Mohamed, F ;

Sugarbaker, PH .

ANNALS OF SURGERY, 2004, 240 (02) :278-285

[7] Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study [J].

Glehen, O ;

Kwiatkowski, F ;

Sugarbaker, PH ;

Elias, D ;

Levine, EA ;

De Simone, M ;

Barone, R ;

Yonemura, Y ;

Cavaliere, F ;

Quenet, F ;

Gutman, M ;

Tentes, AAK ;

Lorimier, G ;

Bernard, JL ;

Bereder, JM ;

Porcheron, J ;

Gomez-Portilla, A ;

Shen, P ;

Deraco, M ;

Rat, P ;

Gilly, FN .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3284-3292

[8] Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment [J].

Hess, V ;

A'Hern, R ;

Nasiri, N ;

King, DM ;

Blake, PR ;

Barton, DPJ ;

Shepherd, JH ;

Ind, T ;

Bridges, J ;

Harrington, K ;

Kaye, SB ;

Gore, ME .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1040-1044

[9]

Jacquet P, 1996, Cancer Treat Res, V82, P359

[10] Primary mucinous ovarian cancer: options for surgery and chemotherapy [J].

Kurnit, Katherine C. ;

Frumovitz, Michael .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (11) :1455-1462

← 1 2 3 →